The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Market heading north as we all get older $5.4bn but there is some stark observations that can be addressed with some positive action
“What does peg the market though is the fact that the treatment is pretty unidimensional. There aren't many options available when it comes to the kind of treatments which are available in the market for this kind of a disease. This is why the treatment options are not going to be available anytime soon. This pegs the global idiopathic pulmonary fibrosis market back a bit.”
https://www.prnewswire.com/news-releases/idiopathic-pulmonary-fibrosis-market-size-to-hit-usd-5326-8-million-in-2028--growing-at-7-1--cagr-says-brandessence-market-research-301560822.html
Has this now been approved it seems to now have all the attached international territories
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022058785&_cid=P10-L8BBWP-77851-1
RNS of late have been regular must be everyone has withdrawal systems, not only have they been regular the quality over the last theee months has been good. The frustration at a guess is that news could be due or with two thumping good products there is hope and sooner will be better.
RNS issues;
Aug 4
Jul 3
Jun 3
May 2
More independent comment from pharma analysts
https://www.europeanpharmaceuticalreview.com/news/173519/big-pharma-deal-making-primed-for-acceleration/
GEN inCodeGEN inCode
GEN inCode
and Covid-19
Contact Us
COVID-19_RISK STRATIFICATION AND PREVENTION
With the onset of the SARS-CoV-2 Coronavirus (COVID-19) pandemic and its high level of mortality in certain population groups, it is advisable to detect personal risk factors that can lead to the accelerated development and increased severity of infection by COVID-19.
From the above article
“Looking ahead, the PwC partners expect dealmaking to continue. They believe large pharmaceutical companies will pursue acquisitions to, among other reasons, bring in new drugs that can help offset the expected losses should some of their key products lose patent protection over the next several years.”
This has been mentioned a few times by different bod members I wonder if an application has been submitted it is separate from the usual approvals. With the research now showing covid cases suffering from IPF it must be a possibility.
https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products
Try this the original
https://www.medscape.com/viewarticle/978522